^
Association details:
| Biomarker: | CD47 overexpression + CD38 underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lemzoparlimab (ABBV-IMAB-TJC4) (CD47 inhibitor) + felzartamab (MOR202) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4462 Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma (rrMM) and the Correlation with CD47 and CD38 Expression
Published date:
11/03/2022
Excerpt:
...the combination of felzartamab and lemzoparlimab effectively enhanced the phagocytosis across all the tested cell lines, the synergistic effect was more prominent in these daratumumab or felzartamab resistant high-risk MM cell lines with CD47 high and CD38 low expression. Third, felzartamab and lemzoparlimab combination elicited synergistic tumor regression in high-risk CDX model which was CD47 high and CD38 low....Combination of lemzoparlimab and felzartamab showed enhanced in vitro ADCP and in vivo anti-tumor efficacy in these CD47 high and CD38 low high-risk MM cells which were resistant to felzartamab or daratumumab mono-treatment.
DOI:
https://doi.org/10.1182/blood-2022-164755
